14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AKRO vs JNJ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas JNJ carries 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin).
Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. JNJ 57.8/100 HOLD), JNJ captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+5.9% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs JNJ. Trailing 12-month operating profitability (AKRO 0.0% vs JNJ 26.6%) and valuation multiples (AKRO N/M vs JNJ 23.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
JNJ Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $643.1B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($40.9B)
90D Engineering Disclosures0 Published
Investor FAQ AKRO vs JNJ Key Questions & Quantitative Answers
As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas JNJ carries 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. JNJ 57.8/100 HOLD), JNJ captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+5.9% vs. +0.0% YoY).
JNJ leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with JNJ at +5.9% YoY revenue growth and -95.9% YoY earnings growth on $99.3B TTM revenue (67.8% gross margin, 26.6% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $99.3B for JNJ. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($40.9B) (0 disclosures) for JNJ.
JNJ screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas JNJ trades at 23.3x Forward P/E, 40.5x Trailing P/E, 3.07x PEG, and 6.8x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus JNJ (20.0% ROE) capital efficiency.
In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, JNJ carries 34.7% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.04β · 25% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.